Septerna, Inc Common Stock

Yahoo Finance • last month

Septerna Reports Positive Phase 1 Data For SEP-631; Plans Phase 2 In CS Urticaria

(RTTNews) - Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering small-molecule therapies targeting G protein-coupled receptors (GPCRs), announced positive results from its Phase 1 clinical trial of SEP-631 for the trea... Full story

Yahoo Finance • last month

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile... Full story

Yahoo Finance • 4 months ago

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy fr... Full story

Yahoo Finance • 5 months ago

Septerna to Participate in 8th Annual Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that managemen... Full story

Yahoo Finance • 5 months ago

Septerna, Inc. GAAP EPS of $0.18, revenue of $21.5M

* Septerna, Inc. press release [https://seekingalpha.com/pr/20300040-septerna-highlights-company-progress-and-reports-third-quarter-2025-financial-results] (SEPN [https://seekingalpha.com/symbol/SEPN]): Q3 GAAP EPS of $0.18. * Revenue... Full story

Yahoo Finance • 6 months ago

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointme... Full story

Yahoo Finance • 7 months ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 8 months ago

Septerna shares drop as quarterly loss widens despite better-than-expected EPS

Investing.com -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, saw its shares fall 4.3% after reporting a widened net loss for the second quarter despite beating earnings... Full story

Yahoo Finance • 8 months ago

Septerna, Inc. GAAP EPS of -$0.56, revenue of $0.1M

* Septerna, Inc. press release [https://seekingalpha.com/pr/20196588-septerna-highlights-business-progress-and-reports-second-quarter-2025-financial-results] (NASDAQ:SEPN [https://seekingalpha.com/symbol/SEPN]): Q2 GAAP EPS of -$0.56.... Full story

Yahoo Finance • 8 months ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans a... Full story

Yahoo Finance • 9 months ago

The Implied Analyst 12-Month Target For AVSC

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 11 months ago

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accel... Full story

Yahoo Finance • 11 months ago

Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal

Eli Lilly (NYSE:LLY) shares slid more than 3% on Wednesday after reports emerged that Novo Nordisk (NYSE:NVO) has struck a licensing deal with Septerna (NASDAQ:SEPN) to co-develop obesity, Type 2 diabetes, and metabolic therapies.Eli Lilly... Full story

Yahoo Finance • 11 months ago

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to... Full story

Yahoo Finance • 11 months ago

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Novo Nordisk A/S Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop multiple oral small mol... Full story

Yahoo Finance • last year

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN) on behalf... Full story

Yahoo Finance • last year

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN). The investigation concerns whether Septerna and/or cert... Full story

Yahoo Finance • last year

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Septerna, Inc. (“Septerna” or “the Company”) (NASDAQ: SEPN) investors that the firm has initiated an investigation into possible securities fraud and may file a... Full story